In the ongoing collaboration between IVI and PAVE Center, University of Maryland, the research team has been working to identify patient-driven priorities for major depressive disorder (MDD) and explore how these priorities can be used to inform value assessments. As part of the project, the research team examined whether efficacy endpoints included in existing empirical evaluations for treatments for MDD captured patient-prioritized value elements. The results of this inquiry were presented during a poster session at the 2022 ISPOR Annual Conference titled “Evidence for a Patient-Informed Approach to Value Assessment of Major Depressive Disorder Treatments.” The findings suggested that existing evaluations focused mostly on response or remission rates, and few addressed quality of life impacts of treatment, which are important to patients. Furthermore, patient-informed priorities can complement existing evaluations to support a more patient-centered evaluation of treatment options and subsequent value assessments.
Click here for a copy of the poster.